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OBJECTIVES: To evaluate changes in anti-glycemic treatment patterns in patients
newly augmenting statin therapy with niacin extended-release (NERS), relative to
patients initiating alternative lipid regimens. METHODS: An observational cohort
study was conducted using integrated administrative claims and laboratory result
data within the HealthCore Integrated Research Database. T2DM patients aged 18
to 64 initiating statin-augmenting therapy (NERS, ezetimibe (EZES), or fenofi-
brate (FFBS)) or statin monotherapy (SM) between 1/1/2005-11/30/2008 (index
date) were included. Patients with 12 months of pre-index eligibility and 1
laboratory result for hemoglobin A1c (HbA1c) within the 12-month period were
included. The utilization and average daily dose (ADD) of anti-glycemic medica-
tions during the 12-month pre-index and follow-up period were compared be-
tween cohorts. RESULTS: A total of 42,250 patients were identified: 2,041 NERS,
6,915 EZES, 3,095 FFBS, and 30,199 SM. Compared to each cohort, NERS pa-
tients were more likely to be male (P0.0001), and have higher prevalence of pre-
existing ischemic heart conditions (P0.0001). NERS patients had lowest pre-
index total cholesterol (174.3  55.2; P0.0001), HDL-C (37.2  10.1; P0.0001),
second lowest LDL-C (93.7 38.4), and second highest TG (245.3 307.0) prior to the
index date. Among oral anti-glycemic therapies, NERS patients were observed to
have the largest decrease in ADD (mg/day) for biguanides (metformin: -155.9 
788.0; P0.0001), sulfonylureas (glimepiride: -0.1  1.9; P  0.0053; glipizide: -0.8 
20.8; P  .0001), TZD’s (pioglitizone: -0.8  8.2; P  0.0210), and incretin mimetic
agents (exenatide: -0.1 3.5; P 0.0012) from pre-index to follow-up. Furthermore,
NERS patients had the smallest increase in ADD of DPP-4’s (sitagliptin: 0.3 17.6;
P  0.0067). CONCLUSIONS: Despite studies indicating the potential for NER to
antagonize glycemic control among T2DM patients, patients initiating NERS were
observed to have decreased utilization and average daily dose of anti-glycemic
medications, relative to alternative treatment regimens.
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OBJECTIVES: To compare medication treatment and 12-month outcomes of pa-
tients aged75 and 75 years who have acute coronary syndromes (ACS) and who
have undergone percutaneous coronary intervention (PCI). METHODS: Data were
from APTOR, robust, prospective, observational registries from 14 European coun-
tries from 2007-2009. Kaplan-Meier (KM) estimates at 12-months post-PCI were
calculated for cardiovascular (CV) event (unstable angina [UA], non-ST-elevation
myocardial infarction [NSTEMI], STEMI, urgent target vessel revascularization,
acute heart failure, ischemic and hemorrhagic strokes or CV death), bleeding, and
mortality by age. RESULTS: 82% were75 years (N3742, median age: 59) and 18%
were 75 years (N803, median age: 79). Older patients tended to be women (38%
vs. 20%); to weigh 60kg (10% vs. 4%); have more hypertension (72% vs. 54%) and
diabetes (26% vs. 20%); have prior MI (28% vs. 18%) and PCI (22% vs. 17%). For
older/younger patients, respectively, the ACS presentation was 25%/22% for UA,
39%/29% for NSTEMI, and 36%/49% for STEMI; treatment at PCI was 14%/10% for
clopidogrel loading doses 300 mg, 24%/33% for GPIIb/IIIa inhibitors, and 5% /11%
for thrombolytic/fibrinolytic therapy. KM (95% CI) estimates for older and younger
patients, respectively, were: 19.8% (17.0%, 22.6%) vs. 13.4% (12.3%, 14.5%) for CV
event, 3.7% (2.4%, 5.1%) vs. 2.6% (2.1%, 3.1%) for bleeding, and 6.8% (5.0%, 8.5%) vs.
1.5% (1.1%, 1.9%) for mortality. CONCLUSIONS: Older patients tended to receive
GPIIb/IIIa and thrombolytic/fibrinolytic therapy less frequently at PCI, contributing
to comparable bleeding rates. However, the higher post-discharge ischemic event
rates suggest that the risk/benefit ratios in the elderly may need to be considered
more carefully. One strategy might be that, if revascularisation is proposed in older
ACS patients, those at lower bleeding risk be treated more aggressively with potent,
newer peri/postprocedural, antiplatelet/antithrombotic management to balance
the post-PCI outcomes disparity at 12 months.
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OBJECTIVES: Market data indicate that simvastatin and atorvastatin, which will
soon come off patent, are prescribed at non-equipotent doses across Europe. We
sought to estimate the differential effects of this on low-density lipoprotein cho-
lesterol (LDL-C) levels and risk of cardiovascular events. METHODS: Weighted av-
erage daily doses (WADDs) of prescribed simvastatin and atorvastatin in 16 West-
ern European countries were derived from IMS data for 2010. Dose-specific, LDL-C
modifying potencies of the 2 statins were derived from the meta-analysis by Nich-
olls et al (Am J Cardiol, 2010). The relationship between reduction in LDL-C
achieved by statin therapy and impact risk of cardiovascular events was derived
from the meta-regression by the Cholesterol Treatment Trialists’ Collaboration
(Lancet, 2010). This showed that for every 1mmol/L reduction in LDL-C, the relative
risk for a major cardiovascular (coronary and/or stroke) event was 0.78 (95%CI
0.76-0.80). RESULTS: Across the 16 Western European countries, the WADDs for
simvastatin and atorvastatin were 28.2mg and 24.4mg, respectively. The corre-
sponding relative reductions in LDL-C at these doses would be 35.8% and 42.0%.
Assuming a pre-treatment LDL-C of 4.0mml/L, these lipid changes would lead to
relative reductions in the risk of a major cardiovascular event of 31.5% and 37.0%,
respectively. In each of the major markets of France, the The Netherlands, Spain,
the UK and Italy, atorvastatin was prescribed at a higher equivalent dose than
simvastatin. Hence it is likely to confer greater potential population cardiovascular
benefits. CONCLUSIONS: In Western Europe, atorvastatin is prescribed at a higher
equivalent dose than simvastatin. The significant advantages of atorvastatin over
simvastatin in terms of LDL-C and cardiovascular risk reduction will be further
enhanced when acquisition prices for atorvastatin fall after its impending loss of
exclusivity.
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OBJECTIVES: This study estimated the effectiveness of rosuvastatin 20mg (R20)
versus atorvastatin 40mg (A40) and 80mg (A80), and rosuvastatin 40mg (R40) versus
A80 in preventing clinical events in several higher cardiovascular-risk patient pop-
ulations using simulation.METHODS:The Archimedes Model was used to simulate
head-to-head clinical trials in several populations based on 10-year Framingham
risk score (FRS) levels (10, 10-20, 20) and EURO-SCORE (5, 5) to estimate the
occurrence of MACE (comprising MI, stroke, and cardiovascular death). Simulated
patients ages 45–70 with FRS 5% were drawn from the National Health and Nu-
trition Examination Survey. Treatment models were validated using biomarker/
outcomes data from published trials. RESULTS: The patient numbers in each FRS
and EURO-SCORE level population ranged from 9190 to 38,313. R20 reduced MACE
more than A40 or A80 and R40 more than A80 in all scenarios, with higher risk
subgroups showing greater absolute benefit. The 5-year number needed to treat
(NNT) to prevent a MACE event for R40 versus A80 for EURO-SCORE5, and5 were
352 and 154 for 5 years and 154 and 72 for 10 years, respectively. The 5-year relative
risk (RR) of MACE for R20 versus A40 was approximately 0.9, irrespective of baseline
risk. The 5-year RR of MACE for R20 versus A80 ranged from 0.92 to 0.94, and for R40
versus A80 it was 0.88 to 0.90. RR estimates were similar at 10 and 20 years; how-
ever, NNT decreased over time. CONCLUSIONS: The Model estimated that R20
lowers the risk of MACE more than A40 or A80, and R40 further lowers risk com-
pared with A80. The estimated absolute risk reduction with rosuvastatin was
greater with higher baseline risk and over time. While simulation models cannot
replace controlled clinical trials, this study highlights the potential of using rigor-
ous modeling approaches to bridge evidence gaps.
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OBJECTIVES: To compare the relative efficacy and tolerability of amiodarone, so-
talol and dronedarone for the treatment of atrial fibrillation (AF) in Australia using
mixed treatment comparisons (MTC). METHODS: There are limited data directly
comparing the safety and effectiveness of dronedarone with the alternatively used
antiarrhythmic drugs (AADs) in Australia. In the absence of direct comparisons, we
have performed an MTC of networks of trials in order to provide best estimates of
the relative effectiveness and safety of the alternative AADs. This approach was
previously used by Freemantle et al (2011) to compare dronedarone not only with
amiodarone and sotalol, but also with flecainide and propafenone. As flecainide
and propafenone are not widely used in Australia, we chose to exclude them from
the current analysis. Literature in AF involving amiodarone, dronedarone, sotalol
or placebo was searched systematically. The 10 selected trials were combined us-
ing MTC models to provide direct and indirect comparisons in a single analysis.
Randomised trials with at least one month of treatment and at least 3 months
follow up were included. RESULTS: Results are presented versus placebo. Trends
towards increased mortality for sotalol (OR 4.67, 95% CI 1.89 – 11.57) and amioda-
rone (OR 2.92, 95% CI 1.17 - 7.31) were found. Conversely, a trend towards decreased
mortality for dronedarone was found (OR 0.87, 95% CI 0.69 – 1.09). CONCLUSIONS:
Using an MTC approach of the AADs available in the Australian clinical setting, we
have shown that dronedarone is associated with a decrease in the risk of all-cause
mortality, and amiodarone and sotalol are associated with an increase in the risk of
all-cause mortality.
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